Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 11/20 | 0.49 |
| ▸ | CA9 | Q16790 | 11/20 | 0.49 |
| ▸ | CA12 | O43570 | 10/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21410215 | 0.98 | CA2 (0.51) | CA2CA5ACA1CA9CA12 | |
| SCHEMBL8863562 | 0.85 | GAA (0.49) | CA2CA5ACA1CA9KIF11 | |
| SCHEMBL2871473 | 0.82 | HSP90AA1 (0.43) | CA2CA5ACA1CA9PTGS2 | |
| SCHEMBL17593373 | 0.82 | ALDH1A1 (0.46) | CA2CA5ACA1CA9KIF11 | |
| SCHEMBL11540331 | 0.80 | CA2 (0.66) | CA2CA5ACA1CA9CA12 | |
| SCHEMBL1172200 | 0.80 | CA2 (0.66) | CA2CA5ACA1CA9CA12 | |
| Hydrazine SCHEMBL28307217 | 0.79 | TSHR (0.52) | CA2CA5ACA1CA9KIF11 | |
| SCHEMBL1005841 | 0.78 | TSHR (0.55) | KIF11ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL2920504 | 0.78 | KIF11 (0.55) | CA2CA1CA9CA12CA3 | |
| SCHEMBL1996062 | 0.78 | ALDH1A1 (0.55) | KIF11ALDH1A1CYP3A4HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240142453-A1 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4209785-A1 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | Ascentawits Pharmaceuticals, Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022048492-A1 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | 深圳艾欣达伟医药科技有限公司 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240142453-A1 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | AKR1C3, AKR1C2, AKR1C1 | CA2 1024/4885CA5A 1198/4885CA1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.